Tempest Therapeutics, Inc. (OVAS) [Rocket]

In millions, except per share items	Jun-30-23	Mar-31-23	Dec-31-22	Sep-30-22	Jun-30-22	Mar-31-22	Dec-31-21	Sep-30-21
	10-Q	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q
Net income	-33.3	-34.9	-35.7	-34.4	-33.5	-31.4	-28.3	-27.9
Depreciation and amortization [+]	0.6	0.7	0.6	0.5	0.4	0.4	0.4	0.3
Depreciation	0.6	0.7	0.6	0.5	0.4	0.4	0.4	0.3
Stock-based compensation	1.8	1.7	1.6	1.4	1.3	1.3	1.1	1.9
Change in working capital [+]	8.9	8.8	11.0	9.1	5.5	11.6	9.6	2.2
Other current assets	0.8	0.7	0.9	-0.7	-0.7	0.3	-0.2	0.3
Accounts payable	-0.7	0.3	0.0	-1.4	-5.2	-0.2	-0.2	0.9
Accrued expenses	0.5	-0.6	1.7	2.0	2.2	2.3	0.7	0.9
Other	8.3	8.3	8.3	9.2	9.2	9.2	9.2
Other operating activities	-8.3	-8.6	-8.5	-9.2	-8.9	-8.6	-8.7	0.2
Cash from operations	-30.2	-32.3	-31.1	-32.6	-35.3	-26.8	-26.0	-23.3

Capital expenditures	-0.6	-0.6	-0.6	-0.2	-0.1	-0.1	-0.1	-0.1
Purchases of property and equipment	-0.6	-0.6	-0.6	-0.2	-0.1	-0.1	-0.1	-0.1
Other cash from investing								0.0
Cash from investing	-0.6	-0.6	-0.6	-0.2	-0.1	-0.1	-0.1	-0.1

Issuance of common stock, net	1.6	7.5	8.9	8.8	11.9	34.8	33.4	33.3
Option exercises							0.1	0.1
Financing costs							-0.1
Other cash from financing			2.5	7.4	7.1		25.7	25.9
Cash from financing	-3.1	10.0	11.4	16.1	18.9	45.5	59.1	59.0

Free cash flow	-30.9	-32.9	-31.6	-32.8	-35.4	-26.9	-26.1	-23.4
Per share (diluted)	($2.33)	($2.60)	($2.88)	($3.63)	($4.85)	($5.78)	($8.74)	($3.46)

Cash paid for interest	1.6	1.6	1.5	1.2	1.1	1.1	1.0	0.7
Cash paid for income taxes	0.1	0.0